3 “Strong Buy” Healthcare Stocks – Week of 1/28

In a world increasingly focused on health and well-being, the healthcare industry stands at the forefront of innovation and growth. The demand for quality healthcare services continues to surge, driven by an aging population, advancements in medical technology, and a global emphasis on preventative care. Investing in strong healthcare stocks presents a compelling opportunity, offering the possibility of robust returns and long-term stability.

Here are three “Strong Buy” Healthcare stocks from Wall Street –

Arcturus Therapeutics Holdings Inc. – SYM: ARCT
Recent Price: $33.19
Price Target: $73.20
Firms with Buy Rating: Piper Sandler, Wells Fargo, Citi
Description: Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. The company was founded in 2013 and is headquartered in San Diego, California.

2024 Stock Alert: Is this an AI Melt Up?


After months of near-vertical gains, cracks are starting to show in the AI “gold rush”…

If you’re looking at the AI stock frenzy and thinking “this can’t end well,” it’s time to move your money…

50-year Wall Street legend names his favorite under-the-radar AI stock for 2024, live on-camera.

AI investing just hit a critical tipping point. The decisions you make now will decide if you have the potential to become fabulously wealthy in 2024.

The trillion-dollar AI “gold rush” just hit a critical tipping point… triggering massive potential gains and losses.

Artificial Intelligence ushers in the “Mother of All Melt Ups.”

Here’s what that means for your money…


Arvinas, Inc. – SYM: ARVN
Recent Price: $41.85
Price Target: $61.07
Firms with Buy Rating: Wells Fargo, Guggenheim, H.C. Wainwright
Description: Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Is Your Money – and Privacy – at Risk?

data protection

A digital dollar could be a major threat to both your money and your personal privacy. See how it might impact your financial freedom and data security – and what you can do to protect both. Be informed, stay ahead.

Protect Your Financial Privacy Now


Cabaletta Bio, Inc. – SYM: CABA
Recent Price: $20.96
Price Target: $33.50
Firms with Buy Rating: Morgan Stanley, Wells Fargo, TD Cowen
Description: Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Trump & Biden BOTH Eliminated?

It doesn’t matter if you’re for Trump…

Or for Biden…

Because new evidence is pointing to NEITHER being the president.

Who will win instead?

Click here to see.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.